Skip to main content

Bladder Cancer Clinical Trials

Review the bladder cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 166

Enfortumab Vedotin with Concurrent Radiation Therapy for the Treatment of Locally Advanced Bladder Cancer, CONSOLIDATE Trial
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
A Beta-only IL-2 ImmunoTherapY Study
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Sacituzumab Govitecan in Combination with Adaptive Radiation Therapy for Treatment of Patients with Muscle Invasive Bladder Cancer, RAD-SG Study
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients with Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Intravesical Romidepsin in Combination with Durvalumab for the Treatment of Localized Muscle Invasive Bladder Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Immunotherapy and Radiation Therapy after Surgery for the Treatment of Patients with Urothelial Bladder Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
A Personalized Cancer Vaccine for the Treatment of Muscle-Invasive Bladder Cancer, Gastroesophageal Cancer, Melanoma, and Non-small Cell Lung Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Status: Active
Location: 2 locations
AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Enfortumab Vedotin and Pembrolizumab Followed by Cystectomy and/or Ureterectomy for the Treatment of Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
A Decision Tool for the Selection of Women with Localized Urothelial Bladder Cancer for Reproductive Organ Sparing Radical Cystectomy
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
A Precision Oncology Navigation and Expert Review Intervention for Improving Referral to Genome Informed Therapy among Patients with Stage IV Lung, Colorectal, Breast or Bladder Cancers, PROGRESS Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Physical Therapy and Coping Skills Training for Improving Women's Sexual Function after Pelvic Radiation
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Status: Active
Location: See ClinicalTrials.gov
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Tesetaxel for Previously Treated Patients With Bladder Cancer
Status: Active
Location: See ClinicalTrials.gov
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Status: Active
Location: See ClinicalTrials.gov